This is a preview of subscription content, log in via an institution to check access.
Reference
Li T, et al. An indirect treatment comparison (ITC) and cost-effectiveness analysis of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-chemotherapy. 2014 Genitourinary Cancers Symposium : abstr. 270, 30 Jan 2014.
Rights and permissions
About this article
Cite this article
Abiraterone acetate equal benefits but lower costs than enzalutamide. PharmacoEcon Outcomes News 699, 4 (2014). https://doi.org/10.1007/s40274-014-1132-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1132-4